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Background: Overweight and obesity are frequently associated with preventable death and 
have emerged as a major challenge to public health. There is an ongoing debate on the role of 
abdominal obesity and its value in predicting cardiovascular and renal outcomes. The present 
analysis evaluates the prevalence of microalbuminuria (MAU) and conventional cardiovascular 
risk factors in relation to measures of general and abdominal obesity.
Methods: In this multinational, observational study, 20828 hypertensive out-patients from 26 
countries including Europe, North and Latin America, Middle East, and Asia were analyzed. 
Urinary dipstick screening for MAU was performed as well as data on patient demographics, 
anthropometric measures, cardiovascular risk factors, comorbid conditions, and cardiovascular 
drug therapy collected. MAU prevalence was determined by a stepwise logistic regression 
analysis with cardiovascular risk factors as univariate.
Results: In the univariate analysis, MAU prevalence systematically increased with body mass 
index (BMI) from 54.4% (1st tertial) to 62.1% (3rd tertial) (p  0.0001), an increase which was 
also observed for waist circumference (WC). At any level of BMI, MAU increased with WC 
from 53.5%, 54.8%, and 55.0% (1st tertial of WC in all three BMI tertials) to 61.4%, 62.1%, 
and 64.0% (3rd tertial of WC in all BMI tertials) (p  0.0001). In the multivariate analysis, 
WC, but not BMI was independently associated with MAU. Furthermore, overweight/obesity 
were associated with the presence of modifiable and nonmodifiable risk factors.
Conclusion: An abnormal WC, but not BMI appears to be independently associated with 
MAU, an early marker of cardiovascular and renal risk. Increasing WC confers an incremental 
risk for MAU at any level of BMI, underlining the prognostic importance of abdominal fat 
accumulation beyond general obesity.
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Introduction
Obesity is frequently associated with preventable death and has emerged as a major 
health care challenge in the 21st century.1 In 2004, an estimated 32% of US adults 
(20 years old) were obese, 4.8% of which were morbidly obese.2 In Europe, obesity 
prevalence in adults differs from country to country, ranging from 10%–25%.3 
Furthermore, a global obesity epidemic in preschool children and adolescents 
seems to be underway4 and highlights the urgent need for prevention. Overweight 
and obesity are frequently and independently associated with minor adverse health 
conditions, such as gallbladder or fatty liver disease, but also with serious illnesses, 
such as cancer.5,6 However, another major concern with obesity is cardiometabolic 
risk, frequently associated with atherosclerotic cardiovascular disease or diabetes.7 Vascular Health and Risk Management 2009:5 578
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There is an ongoing discussion on the particular importance 
of abdominal obesity, associated with an accumulation 
of visceral fat tissue, as an important component of the 
metabolic syndrome and its associated complications.8–10 
The INTERHEART Trial has identified abdominal 
obesity as a major independent risk factor for myocardial 
infarction in a large multiethnic population.11 Microalbu-
minuria (MAU), defined as urinary albumine excretion of 
30–300 mg/24 hours (20–200 mg/L in the spot urine), is 
an established cardiovascular risk indicator in diabetes, 
hypertensive patients, and the general population, and has 
been shown to be associated with endothelial dysfunction 
and to be predictive for coronary artery disease, myocardial 
infarction, stroke, and all-cause mortality.12 Furthermore, 
MAU predicts the progression of diabetic nephropathy and 
is associated with vascular disease, congestive heart failure, 
diastolic dysfunction, and arterial hypertension.13–16 It was 
the aim of the present study, to evaluate the relationship 
between overweight and abdominal obesity with MAU 
and conventional cardiovascular risk factors in a large 
multiethnic hypertensive population. It was hypothesized, 
that abdominal obesity confers an incremental cardiovas-
cular and renal risk which is independent of the presence 
of general obesity.
Methods
A large international, cross-sectional study was conducted 
in 2005/2006 in cardiology outpatient clinics in 26 countries 
worldwide as described previously.17 In brief, 21,794 
patients, aged 18 years with currently treated or newly 
diagnosed arterial hypertension were enrolled into the study. 
In all patients, urinary dipstick screening was performed 
(Microalbustix®; Bayer HealthCare, Basel, Switzerland) 
and prevalence of MAU, defined as an albumin excretion 
of 30, 80, or 150 mg/L, was determined. Furthermore, 
information on patient demographics, anthropometric mea-
sures, cardiovascular risk factors and co-morbid conditions 
as well as cardiovascular drug therapy were collected in 
case report form. In order to evaluate the association of 
overweight/obesity with the cardiovascular risk profile, 
patients were stratified into three tertials of body mass index 
(BMI) and the presence of conventional risk factors and 
cardiovascular drug therapy were evaluated for all three 
groups. The same analysis was performed in overweight 
patients (defined as BMI 25–30 kg/m2) for the low versus 
high tertial of waist circumference (WC). All analyses were 
performed as univariate analysis and descriptive statistics was 
applied. In order to determine the association of MAU with 
overweight/obesity and abdominal obesity, the population 
was again stratified into medians and tertials (for BMI and 
WC) and also according to established cut-off levels for BMI 
(25, 25–30, 30 kg/m2) and WC ( 102 cm vs  102 cm 
for men,  88 cm vs  88 cm for women) and MAU preva-
lence as well as odds ratios (OR) for MAU for each of these 
measures alone or in combination was assessed as univari-
ate analysis. Furthermore a multivariate logistic regression 
analysis was performed as described previously in order to 
evaluate the association of BMI and WC with MAU.17 For 
the analyses, SAS statistical software (version 9.1.3; SAS 
Institute, Cary, NC, USA) was used. Continuous variables 
are depicted as mean values with standard deviation (SD), 
categorical variables as percentages with 95% confidence 
intervals (95% CI). ORs are depicted with 95% CI. Ethics 
committee approval was obtained by all participating sites 
and informed consent forms were signed by all patients prior 
to study enrollment. The study was conducted according to 
the principles defined by the Declaration of Helsinki.
Results
characteristics of the study population
The i-SEARCH study enrolled a total of 21,794 patients, 
out of which 20,868 patients were included in the present 
analysis. Patient-demographics, anthropometric measures, 
risk factor profile, comorbidities as well as cardiovascu-
lar pharmacotherapy were described elsewhere17 and are 
depicted in Table 1.
Description of cardiovascular risk factors 
and pharmacotherapy
When patients were stratified into three BMI tertials, mean 
WC increased with BMI from the low to the high tertial 
(88.7, 99.0, 110.6 cm, respectively). The overweight group 
(BMI 25–30 kg/m2) comprised a total of 43.6% of the overall 
population and there were more men and patients were 
slightly older in the high WC group (110.0 cm) as compared 
to the low WC group (87.3 cm). With increasing BMI, a 
systematic increase in the prevalence of cardiovascular risk 
factors/markers, such as systolic blood pressure (147.8, 148.7, 
151.1 mm Hg, respectively), history of myocardial infarction/
coronary artery disease (24.9%, 28.3%, 30.3%, respectively), 
physical activity (40.0%, 34.7%, 25.8%, respectively), 
dyslipidemia (41.8%, 48.1%, 49.4%, respectively) and type 
2 diabetes (16.1%, 21.5%, 31.2%, respectively) was found. 
The same systematic increase in risk factors/markers was 
seen in the overweight group when comparing the low and Vascular Health and Risk Management 2009:5 579
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Table 1 Patient characteristics
Parameter (mean/%) Total population (n = 20,868)
Demographics Male (%) 52.3
Age (years) 62.4
Anthropometric measures BMi (kg/m2) 28.9
Wc (cm) 99.4
WHR 0.95
Risk factors/markers sBP (mm Hg) 149.1
Family history of Mi/cAD (%) 27.8
exercise 4 hours/week (%) 65.1
exercise 4 hours/week (%) 35.0
Moderate (%) 92.5
strenuous (%) 7.5
never smoked (%) 54.0
current smoker (%) 14.2
no of cigarettes/day 16.3
Duration since stopped smoking (years) 14.8
Known dyslipidemia (%) 46.3
Tc  5.17 mmol/L (%) 52.6
HDL-c  1.16 mmol/L (%) 37.2
Tg  1.69 mmol/L (%) 45.8
Type 2 diabetes mellitus (%) 27.5
Length of diabetes (yrs.) 7.9
HbA1c (%) 6.8
cRP (mg/dl) 0.9
comorbidities Heart failure (%) 5.8
Atrial fibrillation (%) 8.3
LVH (sokol.  35 mm)(%) 14.4
cAD (%) 22.9
History of Mi (%) 53.4
History of myocardial revascularization (% cAD) 57.8
ischemic stroke (%) 4.8
TiA (%) 3.8
Aortic Aneurysm (%) 1.4
PAD (%) 4.2
cardiovascular pharmacotherapy Thiazides (%) 28.3
Loop diuretics (%) 8.7
Aldosterone antagonists (%) 2.7
ccB (%) 32.7
BB (%) 43.7
Acei (%) 38.5
ARB (%) 32.6
AB (%) 3.1
statins (%) 38.1
Fibrates (%) 3.4
AsA (%) 40.0
Other antiplatelet drugs (%) 6.4
Warfarin/coumadin (%) 5.0
Digitalis (%) 3.0
Oral nitrates (%) 6.8
Antiarrhythmics (%) 3.4
1 Diabetes drug (%) 19.8
Abbreviations: BMi, body mass index; cAD, coronary artery disease; cRP, c-reactive protein; HbA1c, glycated hemogobin; HDL-c, high-density lipoprotein-cholesterol; LVH, 
left ventricular hypertrophy; Mi, myocardial infarction; sBP, systolic blood pressure;   Tc, total cholesterol;   Tg, triglycerides; Wc, waist circumference;   WHR, waist-to-hip ratio.Vascular Health and Risk Management 2009:5 580
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the high WC group. In line with the increase in cardiovascular 
risk, more patients received cardiovascular drug therapy with 
increasing BMI as well as increasing WC in the overweight 
group. However, in the overweight group, patients with a 
higher WC did not seem to receive more thiazides, calcium 
channel blockers (CCBs), or angiotensin receptor blockers 
(ARBs) (see Table 2).
Prevalence of MAU in relation to BMi
When patients were stratified into medians and tertials of 
BMI and also three levels of BMI, there was a significant 
increase in the prevalence of MAU, with 55.6% (95% CI: 
54.6, 56.5) in the low versus 61.2% (95% CI: 60.2, 62.1) 
in the high median (p  0.0001), 54.4% (95% CI: 53.2, 
55.6) in the 1st , 58.6% (95% CI: 57.5, 59.8) in the 2nd and 
62.1% (95% CI: 60.9, 63.2) in the 3rd tertial (p  0.0001) 
and 54.4% (95% CI: 52.9, 55.8), 57.6% (95% CI: 56.6, 
58.6) and 61.9% (95% CI: 60.8, 63.0) in patients with 
a BMI of 25, 25–30, or 30 kg/m2 BMI (p  0.0001) 
(Figure 1).
Prevalence of MAU in relation to Wc
When patients were stratified into medians, tertials and 
according to absolute levels of WC, a similar increase in 
MAU was detected. MAU prevalence was 54.6% (95% CI: 
53.6, 55.6) in the low versus 62.1% (95% CI: 61.1, 63.0) in 
the high median (p  0.0001), 53.9% (95% CI: 52.7, 55.1) 
in the 1st, 57.4% (95% CI: 56.2, 58.6) in the 2nd and 63.4% 
(95% CI: 62.3, 64.5) in the 3rd tertiale (p  0.0001). In male 
patients with a WC  102 versus  102 cm, MAU preva-
lence was 59.0% (95% CI: 57.7, 60.3) and 64.7% (95% CI: 
63.3, 66.0), respectively (p  0.0001), whereas in women, 
overall prevalence was markedly lower with 50.3% (95% 
CI: 48.5, 52.1) in the group with a waistline of 88 cm 
and 56.9% (95% CI: 55.7, 58.1) in women with a waistline 
of  88 cm (p  0.0001) (Figure 2).
Prevalence of MAU in relation to Wc 
at different levels of BMi
In order to evaluate the predictive values of WC for MAU 
in patients at different levels of overweight/obesity, three 
Table 2 Patient characteristics by BMi tertial and Wc tertial (high vs low) in overweight patients (BMi 25–30 kg/m2)
Parameter (mean/%) BMI (kg/m2) BMI 25–30 kg/m2
1st tertial  
(N = 6948)
2nd tertial  
(N = 6969)
3rd tertial  
(N = 6951)
WC 1st tertial  
(N = 3090)
WC 3rd terital  
(N = 2169)
Demographics Male (%) 49.9 57.8 49.0 35.3 77.3
Age (years) 63.2 62.7 61.4 61.6 64.1
Anthropometr measures BMi (kg/m2) 23.9 28.2 34.6 27.0 28.1
Wc (cm) 88.7 99.0 110.6 87.3 110.0
Risk factors/markers sBP (mm Hg) 147.8 148.7 151.1 147.9 149.4
Family history of Mi/cAD (%) 24.9 28.3 30.3 27.2 29.6
exercise 4 hours/week (%) 40.0 34.7 25.8 36.5 33.9
Known dyslipidemia (%) 41.8 48.1 49.4 44.6 48.0
Tc  5.17 mmol/L (%) 50.7 52.3 55.0 54.4 51.5
HDL-c  1.16 mmol/L (%) 317 39.0 40.6 31.6 44.9
Tg  1.69 mmol/L (%) 38.8 45.5 52.8 41.4 50.4
Type 2 diabetes mellitus (%) 16.1 21.5 31.2 16.6 23.2
cardiovascular 
pharmacotherapy
Thiazides (%) 25.9 27.9 30.9 27.5 27.0
Aldosterone antagonists (%) 2.5 2.2 3.4 2.1 2.7
ccBs (%) 32.2 31.8 34.0 31.4 31.4
BBs (%) 41.8 43.6 45.6 43.2 44.8
Aces (%) 36.3 38.4 40.8 33.9 41.2
ARBs (%) 30.6 33.2 34.0 34.6 32.8
ABs (%) 2.7 2.8 3.8 2.5 3.5
statins (%) 34.9 39.1 40.2 35.4 40.9
Abbreviations: Abs, alpha blockers; Aces, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; BBs, beta blockers; BMi, body mass index; cAD, 
coronary artery disease; ccBs, calcium channel blockers; HDL-c, high-density lipoprotein-cholesterol; Mi, myocardial infarction; sBP, systolic blood pressure;   Tc, total cholesterol; 
Tg, triglycerides; Wc, waist circumference.Vascular Health and Risk Management 2009:5 581
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tertials of WC were analyzed within each tertial of BMI. 
Within all three BMI groups, there was a graded increase in 
MAU from the low to the high WC tertial: MAU was pres-
ent in 53.5% (95% CI: 52.0, 54.9) in the low versus 61.4% 
(95% CI: 56.6, 66.1) in the high WC tertial (1st BMI tertial, 
p  0.0001), 54.8% (95% CI: 52.4, 57.2) in the low versus 
62.1% (95% CI: 60.0, 64.2) in the high WC tertial (2nd BMI 
tertial, p  0.0001) and 55.0% (95% CI: 49.7, 60.1) in the 
low versus 64.0% (95% CI: 62.7, 65.4) in the high WC tertial 
(3rd BMI tertial, p  0.0001) (Figure 3).
Odds ratio for MAU according to BMi, 
Wc alone, or in combination
In the univariate analysis, patients with a higher BMI had 
an increased risk of MAU with ORs ranging from 1.26 
(95% CI: 1.19, 1.33) to 1.37 (95% CI: 1.28, 1.47) for the 
high versus low median or tertial, and 1.36 (95% CI: 1.26, 
1.47) for obese patients (30 kg/m2) versus those at normal 
weight (25 kg/m2). Also patients with a higher WC are at 
an increased risk for MAU with an OR of 1.36 (95% CI: 
1.29, 1.44) and 1.48 (95% CI: 1.38, 1.58) for the high ver-
sus low median or tertial. In men with a waistline 102 cm 
versus 102 cm, OR for MAU was 1.27 (95% CI: 1.18, 
1.38), a finding which was also confirmed in women, where 
OR was 1.30 (95% CI: 1.19, 1.42) for a high (88 cm) versus 
low waistline (88 cm). Within each tertial of BMI, a high 
versus low waistline was associated with an increased risk of 
MAU, ranging from 1.38 (95% CI: 1.12, 1.69) for the 1st , to 
1.47 (95% CI: 1.18, 1.82) for the 3rd BMI tertial (p  0.0001) 
(see Figure 4a). In the multivariate analysis, an abnormal 
versus normal WC (defined as 102 cm versus 102 cm 
for men and 88 cm versus 88 cm for women), but not 
BMI, was independently associated with MAU (OR 1.132, 
95% CI: 1.039, 1.233) (see Figure 4b).
Discussion
Excess in body fat mass can be measured by defining a 
subjects BMI (height-independent measure of weight), WC 
(marker of abdominal/viszeral excess fat) or waist-to-hip 
ratio (WHR; body shape in relation to fat deposition). An 
increase in BMI can indicate an increase in total body fat and 
has been shown not only to be linked with comorbidities such 
as hypertension, diabetes, coronary heart disease, but also 
with total mortality in men and women of different ethnic 
origin.18–20 Its value in predicting cardiovascular risk has been 
challenged by the results of the INTERHEART Study.11,21 
According to this trial abdominal obesity, measured by 
WHR but less so by BMI, was shown to be an independent 
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Figure 1 Prevalence of MAU in relation to BMi.
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risk factor for the incidence of myocardial infarction. Our 
data from a large multiethnic sample of more than 20,000 
hypertensive patients confirm that increases in BMI are 
associated with several important atherogenic risk factors, 
such as lack of exercise, dyslipidemia, total cholesterol, 
high-density lipoprotein (HDL)-cholesterol, triglycerides, 
and presence of diabetes. Our data also clearly confirm 
the elevated risk profile of abdominally obese patients, by 
showing a higher overall prevalence of modifiable- and non-
modifiable risk factors in patients with an excess in abdominal 
fat. Beside these correlations, we sought to determine the risk 
of cardiovascular and renal end organ damage measured by 
MAU, an established surrogate marker of adverse cardiovas-
cular and renal outcomes, and its correlation with different 
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Figure 4a Odds ratio for MAU for BMi, Wc and BMi & Wc (Univariate analysis).
Abbreviations: BMi, body mass index; CI, confidence interval; MAU, microalbuminuria; OR, odds ratio; WC, waist circumference.
measures of obesity. In three small studies, no relationship 
between MAU and BMI, WC, WHR, or visceral obesity, 
measured by computed tomography, could be detected.22–24 
In contrast, analyses from the DCCT/EDIC (Diabetes Control 
and Complications/Epidemiology of Diabetes Interventions 
and Complications) population in diabetic men and women 
showed that WHR, but not BMI, was associated with an 
abnormal urinary albumin excretion rate.25,26 In our study, a 
linear relationship between BMI and MAU was detected in 
the univariate analysis: Across all categories of BMI, MAU 
prevalence increased significantly with BMI by absolute 
8% from the 1st to 3rd tertial (Figure 1). In addition, WC 
showed a linear relationship with the prevalence of MAU, 
which increased by absolute 9% from the lowest to the highest 
WC tertial (Figure 2). Furthermore, these data show that 
within each BMI tertial, a high versus low WC appears to 
be associated with a higher MAU prevalence, supporting the 
notion of abdominal obesity confering an incremental risk for 
early renal and cardiovascular damage at any level of BMI.
In patients with abdominal obesity, a specific constellation 
of cardiovascular risk factors and markers, such as elevated 
blood pressure, low HDL-cholesterol, hypertriglyceridemia, 
elevated blood glucose, and insulin levels (impaired glucose 
tolerance) are clustered, findings which were confirmed 
by our data. This population shows a doubled risk for 
developing cardiovascular disease or diabetes.8 Moreover, 
recent data from similar populations demonstrated WC to 
be superior to BMI in predicting cardiovascular risk in men 
and women. Also in a recent analysis in 24,000 patients, 
WC was a better predictor for an increased risk of coronary 
artery disease than BMI,27 results which were supported by 
the INTERHEART study indicating, that abdominal obesity 
measured by WHR represents an independent risk factor for 
the incidence of myocardial infarction.11 We therefore also 
conducted a multivariate logistic regression analysis in order 
to evaluate the specific relationship of WC and BMI with 
MAU after adjustment for various confounding variables. In 
our multivariate model, WC, but not BMI, was identified as 
an independent marker of renal and cardiovascular risk by 
using MAU as a surrogate marker, thereby confirming the 
findings from INTERHEART and Canoy and colleagues11,27 
in this large sample of hypertensive patients.Vascular Health and Risk Management 2009:5 584
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At present, the specific pathophysiological link between 
obesity and MAU can only be speculated. Abdominal 
obesity represents a key component of the metabolic 
syndrome. The crucial components that may link abdominal 
obesity to other features of the metabolic syndrome and 
end-organ damage are presumably elevated insulin levels, 
peripheral tissue resistance to the insulin-sensitizing 
action of leptin, and increased macrophage infiltration in 
fat tissues with concomitant release of proinflammatory 
cytokines.28,29 The described metabolic changes favor 
intracellular lipid deposition in adipose tissue, hepatocytes, 
skeletal and cardiac myocytes as well as in endothelial 
cells.30,31 Intracellular fat deposits, associated with inflam-
matary cytokines and ischemia (pro-thrombotic state), 
frequently associated with abdominal obesity, might 
decrease the functional integrity of the endothelial wall 
and lead to MAU.
Taken together, the data presented from this large 
international cohort of hypertensive patients confirms the 
presence of an increased cardiovascular risk profile in 
patients with overweight and specifically abdominal obesity. 
Futhermore, a linear relationship of different measures of 
overweight/obesity with MAU, an established marker of 
cardiovascular disease and renal damage, was detected. 
However, only abdominal obesity, as measured by WC 
was independently associated with a higher prevalence 
of MAU. The data supports the current perception of the 
pathophysiological role of an excess in viszeral fat and 
underlines the importance of weight loss-efforts as essential 
goal in cardiovascular risk management and possibly also 
the prevention of renal damage.
Limitations
At present, it can only be speculated whether the observed 
relationship between overweight/obesity and MAU is 
similar across all ethnic groups included into the present 
analysis. However, since the study population was domi-
nated by patients from western countries (about 15,500 
patients), the conclusions mostly apply to Caucasian 
populations. For this reason, the present analysis also 
evaluated MAU in relation to specific cut-off levels of 
BMI and WC, recommended by international guidelines 
for this population. The main analysis was performed by a 
single dipstick screening test for MAU, where international 
guidelines recommend, that MAU should be established 
by three separate tests out of which two measurements 
should be positive. However, dipstick testing at one single 
occasion has been established as a usefull screening tool 
in epidemiological research.
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Figure 4b Odds ratio for MAU for BMi & Wc (Multivariate analysis).
Abbreviations: BMi, body mass index; CI, confidence interval; MAU, microalbuminuria; OR, odds ratio; WC, waist circumference.Vascular Health and Risk Management 2009:5
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